The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abstract
OBJECTIVES: The objective of this study was to evaluate short- and long-term outcomes of infliximab in ulcerative colitis (UC), including infliximab optimization, colectomy, and hospitalization. METHODS: This was a retrospective multicenter study. All adult patients who received at least one infliximab infusion for UC were included. Cumulative probabilities of event-free survival were estimated by the Kaplan-Meier method. Independent predictors were identified using binary logistic regression or Cox proportional-hazards regression, and results were expressed as odds ratios or hazard ratios (HRs), respectively. RESULTS: Between January 2000 and August 2009, 191 UC patients received infliximab therapy. Median follow-up per patient was 18 months (interquartile range=25-75th, 8-32 months). Primary non-response was noted in 42 patients (22.0%). "Hemoglobin at infliximab initiation ≤ 9.4 g/dl" (odds ratio=4.35; 95% confidence interval (CI)=1.81-10.42) was a positive predictor of non-response to infliximab. Infliximab optimization was required in 36 (45.0%) of 80 patients on scheduled infliximab therapy. The only predictor of infliximab optimization was "infliximab indication for acute severe colitis" (HR=2.75; 95% CI=1.23-6.12). Thirty-six patients (18.8%) underwent colectomy. Predictors of colectomy were: "no clinical response after infliximab induction" (HR=7.06; 95% CI=3.36-14.83), "C-reactive protein at infliximab initiation > 10 mg/l" (HR=5.11; 95% CI=1.77-14.76), "infliximab indication for acute severe colitis" (HR=3.40; 95% CI=1.48-7.81), and "previous treatment with cyclosporine" (HR=2.53; 95% CI=1.22-5.28). Sixty-nine patients (36.1%) were hospitalized at least one time and UC-related hospitalizations rate was 29 per 100 patient-years (95% CI=24-35 per 100 patient-years). Predictors of first hospitalization were: "no clinical response after infliximab induction" (HR=3.87; 95% CI=2.29-6.53), "infliximab indication for acute severe colitis" (HR=3.13, 95% CI=1.65-5.94), "disease duration at infliximab initiation ≤50 months" (HR=2.14, 95% CI=1.25-3.66), "hemoglobin at infliximab initiation ≤11.8 g/dl" (HR=1.77; 95% CI=1.03-3.04), and "previous treatment with methotrexate" (HR=0.30; 95% CI=0.09-0.97). CONCLUSIONS: Primary non-response to infliximab was noted in one fifth of patients and increased by seven and four the risks of colectomy and hospitalization, respectively. Infliximab optimization, colectomy, and hospitalization were required in half, one fifth, and one third of patients, respectively. Infliximab indication for acute severe colitis increased by three the risks of infliximab optimization, colectomy, and UC-related hospitalization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Nachury, M., Moreau, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61084-8 · Cited by 646
Self-citationBrandse, J. F., van den Brink, G. R., Wildenberg, M. E., van der Kleij, D., Rispens, T., Jansen, J. M., Mathôt, R. A., Ponsioen, C. Y., Löwenberg, M., & D’Haens, G. R. A. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.016 · Cited by 433
Shah, S. C., Colombel, J.-F., Sands, B. E., & Narula, N. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.01.015 · Cited by 360
European evidence based consensus on surgery for ulcerative colitis
Øresland, T., Bemelman, W. A., Sampietro, G. M., Spinelli, A., Windsor, A., Ferrante, M., Marteau, P., Zmora, O., Kotze, P. G., Espin-Basany, E., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.012 · Cited by 353
Metadata
- Authors
- Oussalah, A., Evesque, L., Laharie, D., Roblin, X., Boschetti, G., Nancey, S., Filippi, J., Flourié, B., Hebuterne, X., Bigard, M.-A., & Peyrin-Biroulet, L.
- Venue
- American Journal of Gastroenterology
- Published
- 2010-12
- Volume
- 105
- Issue
- 12
- Pages
- 2617-2625
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2079185331
- Cited by
- 182
- References
- 1
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. https://app.cochat.ai/papers/10.1038/ajg.2010.345
- The paper
- Oussalah, A., Evesque, L., Laharie, D., Roblin, X., Boschetti, G., Nancey, S., Filippi, J., Flourié, B., Hebuterne, X., Bigard, M.-A., & Peyrin-Biroulet, L. (2010). A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2010.345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.